Related references
Note: Only part of the references are listed.FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
Atish Mohanty et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment
Niklas von Spreckelsen et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
NF2/Merlin suppresses proliferation and induces apoptosis in colorectal cancer cells
Xingli Wu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2020)
CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment
Itishree Kaushik et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2019)
Advances in meningioma genetics: novel therapeutic opportunities
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2018)
Genomic profile of human meningioma cell lines
Yu Mei et al.
PLOS ONE (2017)
Role of Merlin/NF2 inactivation in tumor biology
A. M. Petrilli et al.
ONCOGENE (2016)
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Victoria E. Clarke et al.
NATURE GENETICS (2016)
PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss
Matthieu Peyre et al.
ONCOTARGET (2015)
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer
Nina R. Shah et al.
GYNECOLOGIC ONCOLOGY (2014)
Re-evaluation of cytostatic therapies for meningiomas in vitro
Annette Wilisch-Neumann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
Irina M. Shapiro et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models
Doreen Pachow et al.
CLINICAL CANCER RESEARCH (2013)
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos et al.
NATURE GENETICS (2013)
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark et al.
SCIENCE (2013)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status
Stephane Goutagny et al.
CLINICAL CANCER RESEARCH (2010)
Pathological classification and molecular genetics of meningiomas
Christian Mawrin et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Nf2/Merlin: a coordinator of receptor signalling and intercellular contact
M. Curto et al.
BRITISH JOURNAL OF CANCER (2008)
An orthotopic skull base model of malignant meningioma
Gilson S. Baia et al.
BRAIN PATHOLOGY (2008)
NF2 mutations in secretory and other rare variants of meningiomas
C Hartmann et al.
BRAIN PATHOLOGY (2006)
Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma
F Nunes et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Merlin neutralizes the inhibitory effect of Mdm2 on p53
H Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse
M Kalamarides et al.
GENES & DEVELOPMENT (2002)
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44
H Morrison et al.
GENES & DEVELOPMENT (2001)
Share Paper
